AI-Delivered Short Video Cognitive Behavioral Therapy for Type 2 Diabetes Mellitus - A Randomized Controlled Trial Protocol
Related Experiment Videos
Yijing Zhao1,2, Su Wang2, Yu Yang2
1Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, People's Republic of China.
Background:
This article presents a protocol for a randomized, controlled, multicenter trial that aims to evaluate whether the cognitive behavioral therapy (CBT) based on artificial intelligence (AI) short video push technology can improve glycemic control in patients with type 2 diabetes mellitus (T2DM) more effectively than traditional standard care. CBT has been shown to improve glycemic control in patients with T2DM. To help T2DM patients have and preserve behavioral changes for a long time, we have developed a self-management application TANKON. Patients can receive CBT of diabetes-related knowledge and skills by watching different short videos automatically played in the application, and the orders and content of short videos are precisely calculated based on AI technology.
Methods:
This is a non-blinded, multicenter, parallel-group, randomized controlled trial with 1:1 equal randomization. A total of 298 participants (149 per group) will be enrolled from seven endocrinology departments across general hospitals in China. The intervention group (n = 149) will receive CBT via the TANKON app, an AI-powered platform that automatically delivers short educational videos. The control group (n = 149) will receive care-as-usual. In the following 12-week follow-up, the patients in the intervention group will choose to prolong or discontinue the use of the application. The primary endpoint is the difference in hemoglobin A1c (HbA1c) change from baseline to 12 weeks for the intervention group compared with those assigned to the control group. Safety assessment includes hypoglycemia events and other adverse events.
Conclusion:
This trial evaluates CBT based on AI short video push technology which has the potential to provide a scalable treatment option for patients with T2DM.
Trial Registration:
Trial-ID: ChiCTR2400080050, registration date: 18 January 2024 (https://www.chictr.org.cn/showproj.html?proj=216374).
Related Concept Videos
Type II Diabetes I: Introduction
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type II Diabetes II: Pathophysiology
Diabetes Mellitus: Type 2 and Gestational
Type I Diabetes I: Introduction